latest update:
[TrialBase DB]

trial summary · NCT07454707

Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial

Randomized Trial to Evaluate the Efficacy and Safety of Very Low Dose Anticoagulant Therapy Added to Standard-Care Single Antiplatelet Therapy for Prevention of Recurrent Strokes in Patients With Ischemic Stroke Aged 75+ Years

Trial record from the TrialBase DB dataset, status RECRUITING, condition Stroke, Ischemic, sponsored by Sunnybrook Health Sciences Centre. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07454707phase PHASE3enrollment 1204start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to help prevent recurrent strokes. However, an antiplatelet medication may not be effective enough for some patients. A promising new treatment strategy to enhance stroke prevention involves a very low dose of an anticoagulant (anti-clotting medication) added to the standard antiplatelet therapy. In a previous study, this approach cut stroke risk in half among patients with heart/vascular disease, but it has not yet been formally tested in an older stroke population. The STROKE75+ trial is now being conducted to carefully evaluate the potential benefits and potential risks of this type of treatment strategy for secondary stroke prevention. The medication being tested in the STROKE75+ trial is a commonly used anticoagulant called edoxaban -- at a reduced dose of 15mg once daily (one-quarter of its full dose) to minimize the chance of bleeding. In previous research, edoxaban 15mg daily has been shown to be safe and effective for preventing strokes in patients with atrial fibrillation, but it has not been studied in stroke patients without atrial fibrillation. This trial aims to answer the following questions: 1. Does the addition of edoxaban 15mg once a day to standard antiplatelet therapy reduce the risk of recurrent strokes more than standard antiplatelet therapy alone? 2. Does the addition of edoxaban 15mg daily reduce the risk of severe (disabling) …

Source record: https://clinicaltrials.gov/study/NCT07454707

Facts

registry idNCT07454707
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionStroke, Ischemic
sponsorSunnybrook Health Sciences Centre
sponsor classOTHER
enrollment1204
start date2026-11
primary completion2031-12
completion2031-12
results postednot reported

Conditions

  • Stroke, Ischemic

Interventions

  • Edoxaban 15 mg
  • Aspirin or clopidogrel

Countries

  • Canada

Intervention types: DRUG

Work with this record